{"filings":[{"id":451836,"accession_number":"0001193125-26-224771","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2026-05-15T01:30:16+00:00","items":["5.07"],"status":"ready","headline":"Amarin shareholders reject four proposals at AGM, limiting equity grants and forcing cash compensation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issuance Proposal (authority to issue shares up to £37.75M) failed with 75M for, 96M against.","2020 Stock Incentive Plan amendment to add 15M ordinary shares failed with 71M for, 95M against.","Pre-emption Proposal and Amended Articles Proposal also failed; Say-on-Pay passed but 81M votes against.","Board expects future incentive compensation to be cash-only due to inability to grant equity; cash position impacted.","Company will continue paper delivery of proxy materials, incurring needless printing and mailing costs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.15,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99578,"accession_number":"0001193125-26-188935","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amarin Q1 total revenue up 7% to $45.1M; operating loss narrows 32%; cash flow positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total net revenue $45.1M (+7% YoY); U.S. product revenue $35.6M flat; European revenue $4.9M (-9%); ROW $2.8M.","Operating loss narrowed to $11.3M from $16.8M; net loss $10.5M ($0.03 EPS) vs $15.7M ($0.04 EPS).","Cash and investments $307.8M; debt-free; second consecutive quarter of positive cash flow.","Reaffirms full-year 2026 positive cash flow; targeting ~$70M cost savings; restructuring charges $39.6M cumulative.","Recordati launched VAZKEPA in 10 European countries; U.S. VAZCEPA branded Rx up 17% YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":45132000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115661,"accession_number":"0001193125-26-129334","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Amarin board shrinks from 9 to 7; directors Cohen, O'Connor resign; new compensation policy","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Directors Paul Cohen and Oliver O'Connor will not stand for re-election; resign effective before 2026 annual meeting.","Board size reduced from nine to seven members effective at the same time.","New director compensation policy: annual retainers ($62.5k or $95k for chair); equity awards of $262.5k (initial) and $175k (annual).","Equity grants conditional on shareholder approval of issuance and pre-emption proposals at the 2026 meeting; otherwise cash alternatives considered.","Directors will receive a $175,000 restricted cash award for 2025 meeting equity in lieu of prior year grant."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115660,"accession_number":"0001193125-26-068511","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amarin Q4 net loss narrows to $1.2M; revenue down 21% but cash up and positive cash flow expected in FY26","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net loss improved 97% to $(1.2)M ($0.00 per share) from $(48.6)M in Q4 2024.","Total net revenue $49.2M, down 21% YoY on U.S. price decline and prior-year ROW stocking order.","Operating loss narrowed 88% to $6.3M; restructuring delivered $31M of expected $70M savings.","Cash and investments $302.6M, up $8.4M YoY and $16M sequentially; debt-free.","Management expects positive full-year cash flow in 2026, ahead of schedule."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":213646000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115659,"accession_number":"0001193125-26-006992","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amarin achieves positive cash flow in Q4 2025 ahead of schedule; FY revenue $212-217M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Year-end cash $303M, up $16M from Q3; no debt; Q4 positive cash flow achieved earlier than forecast.","Q4 2025 net revenue expected $48-53M; FY 2025 net revenue $212-217M.","Restructuring: 50% of $70M OPEX savings realized; full benefit on track by June 30, 2026. Estimated restructuring costs raised to $37-40M.","VASCEPA >50% IPE prescription share in US; Recordati now managing European commercialization in most launched countries.","Two new regulatory approvals (South Korea and Singapore); >10 abstracts and >20 manuscripts published in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":213646000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132091,"accession_number":"0001193125-25-254620","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amarin Q3 net revenue $49.7M (+17% YoY), operating loss narrows 56% to $11.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total net revenue $49.7M, up 17% YoY, driven by US sales rebound and exclusive PBM status.","Operating loss of $11.1M improved from $25.2M; SG&A down 47% to $19.7M after restructuring.","Completed transition to fully partnered commercial model (Recordati in Europe); targeting positive free cash flow in 2026.","US product revenue $40.9M (+34% YoY); Europe $4.1M (-5%); Rest-of-World $3.6M (-48%).","Net loss $7.7M ($0.02 EPS) vs $25.1M ($0.06 EPS) last year; cash $286.6M, debt-free."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":164427000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132090,"accession_number":"0001193125-25-246973","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2025-10-22T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Amarin promotes David Keenan to EVP, COO effective October 17, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Keenan, previously EVP Technical Operations and President of Europe, appointed COO effective Oct 17, 2025.","Dr. Keenan joined Amarin in May 2022 as SVP Technical Operations; promoted to EVP in July 2023.","No change to compensation as a result of the COO appointment; no family relationships or arrangements.","Keenan brings over 30 years leadership in biopharma; holds PhD in Organic Chemistry and MBA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148668,"accession_number":"0000950170-25-099878","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amarin Q2 net loss $14.1M; signs European licensing deal with Recordati, plans restructuring","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net loss of $14.1M ($0.03 per share) vs. $1.5M net income in Q2 2024.","Total net revenue $72.7M (+8% YoY); licensing revenue up 31% on Recordati upfront.","Signed exclusive European licensing agreement with Recordati for VAZKEPA in 59 countries.","Global restructuring expected to deliver $70M in operating expense savings over 12 months.","Cash $298.7M, debt-free; U.S. product revenue down 17% to $36.5M, Europe up 85% to $6.6M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":114757000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148667,"accession_number":"0000950170-25-093444","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K/A","filed_at":"2025-07-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Amarin appoints Michael Torok to board; cash award replaces equity due to shareholder pre-emption issue","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Torok appointed non-employee director effective April 4, 2025; joins Remuneration Committee July 1, 2025.","Restricted cash award of $175,000 in lieu of annual equity award, vesting at 2026 Annual Meeting.","Conditional initial equity award of $262,500 (75% options, 25% RSUs) if shareholders approve pre-emption waiver at 2026 meeting; vests over three years.","If board service ends before equity grant, vested portion settled in cash."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167536,"accession_number":"0000950170-25-089218","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["1.01","2.05","7.01","9.01"],"status":"ready","headline":"Amarin licenses VAZKEPA to Recordati in Europe; launches restructuring targeting $70M annual savings","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront $25M and up to $150M in milestone payments; Recordati to commercialize VAZKEPA in 59 European countries.","Global restructuring to cut operating costs by ~$70M annually; expects $30-37M in restructuring charges in Q2 2025.","Company retains U.S. rights; nearly $300M cash on hand, no debt; accelerated path to positive cash flow.","Agreement term 15 years, auto-renewal subject to commercialization in at least one country."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167535,"accession_number":"0000950170-25-072817","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Amarin shareholders reject proposal to allow share allotment without pre-emption rights at AGM","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Special resolution to allot 10% of shares without pre-emption rights failed (89.8M for, 36.0M against; needed 75%).","Board must now seek opt-out for each share issuance, described as time-consuming, expensive and subject to rejection.","Non-employee directors likely to receive supplemental cash compensation in lieu of equity at previously approved value, impacting cash.","All other 12 proposals, including director re-elections and say-on-pay, were approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167534,"accession_number":"0000950170-25-064980","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amarin Q1 2025 net revenue $42M (-26% YoY); net loss $15.7M, wider than prior year","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total net revenue $42.0M vs $56.5M in Q1 2024, down 26% due to generic competition in U.S.","U.S. net product revenue $35.7M (down from $48.1M); Europe rose to $5.4M (from $1.9M).","GAAP net loss $15.7M ($0.04/sh) vs $10.0M ($0.02/sh) in Q1 2024; adjusted net loss $9.4M ($0.02/sh).","Cash & investments $281.8M at March 31, 2025, vs $308.2M a year earlier.","Regained Nasdaq compliance after 1-for-20 ADS ratio change effective April 11, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":42017000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167533,"accession_number":"0000950170-25-060165","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2025-04-29T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"Amarin regains Nasdaq minimum bid price compliance after ADS ratio change","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Received Nasdaq confirmation on April 29, 2025 that bid price averaged ≥$1.00 over 10 consecutive days.","Compliance achieved after adjusting ADS-to-ordinary share ratio from 1:1 to 1:20 on April 11, 2025.","Company now fully compliant with all Nasdaq listing standards; delisting matter closed.","CEO Aaron Berg states focus remains on maximizing global value of VASCEPA/VAZKEPA.","AMRN will continue trading on the Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167532,"accession_number":"0000950170-25-052307","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2025-04-09T23:59:59+00:00","items":["3.03","7.01","9.01"],"status":"ready","headline":"Amarin confirms 1-for-20 ADS reverse split effective April 11 to meet Nasdaq $1 minimum bid","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ADS ratio changes from 1:1 to 1:20 effective April 11, 2025, to meet Nasdaq $1.00 minimum bid price.","No assurance that post-split ADS price will equal or exceed 20x pre-split price.","Certificated ADS holders must surrender; DRS/DTC holders automatic exchange. No fractional ADSs issued.","Fractional entitlements sold; net cash proceeds distributed to holders by depositary bank.","Ordinary shares unchanged; trading symbol remains AMRN."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167531,"accession_number":"0000950170-25-051353","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2025-04-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Amarin appoints Michael Torok (JEC Capital Partners) to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Torok appointed to Amarin board effective April 4, 2025.","Torok is Co-Founder and Managing Director of investment firm JEC Capital Partners.","He will stand for election at the 2025 annual general meeting.","Torok has not been assigned to any board committees initially.","He will receive standard non-employee director compensation per company policy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184827,"accession_number":"0000950170-25-046873","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2025-03-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Mark DiPaolo to step down at Amarin's May 2025 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark DiPaolo will not stand for re-election and leaves the Board after the 2025 Annual Meeting expected in May.","Departure is not due to any disagreement with the company on operations, policies, or practices.","DiPaolo's board service ends at the meeting; no replacement announced yet."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184826,"accession_number":"0000950170-25-037618","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2025-03-12T23:59:59+00:00","items":["2.02","3.03","7.01","9.01"],"status":"ready","headline":"Amarin Q4 revenue $62.3M, net loss $48.6M; announces 1-for-20 ADS reverse split to maintain listing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total net revenue $62.3M, down 17% YoY; net loss $48.6M vs $5.8M loss in Q4 2023.","U.S. VASCEPA revenue fell to $44.2M from $64.9M on generic competition; European revenue rose to $4.0M, RoW to $11.9M.","Cash and investments $294.2M at Dec 31, 2024, down from $320.7M a year earlier; no debt.","Announces 1-for-20 ADS reverse split effective ~April 11, 2025 to comply with Nasdaq $1 minimum bid price.","Non-GAAP adjusted net loss $8.7M ($0.02/ADS) vs adjusted loss $0.9M in Q4 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201421,"accession_number":"0000950170-24-137894","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2024-12-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Amarin appoints Peter Fishman as CFO effective December 13, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Fishman previously served as Global Controller and principal financial & accounting officer since October 2024.","Annual base salary set at $400,000 with bonus potential up to 40% of base.","Fishman has nearly 20 years of finance experience; reports to CEO Aaron Berg.","He is a CPA with an MBA from Rowan University and a BA in accounting from American University."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201420,"accession_number":"0000950170-24-130263","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2024-11-22T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Amarin gets Nasdaq extension to May 19, 2025 for minimum bid price compliance; shares transfer to Capital Market","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq granted 180-day extension until May 19, 2025 to meet $1.00 minimum bid price.","ADS will transfer from Nasdaq Global Market to Capital Market effective Nov 26, 2024.","Compliance achieved if closing bid price is at least $1.00 for 10 consecutive business days.","Company considering options including a reverse stock split to remedy the deficiency.","No guarantee of regaining compliance; delisting remains a possibility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201419,"accession_number":"0000950170-24-118988","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amarin Q3 net revenue $42.3M (-36% YoY); European revenue grows, U.S. declines on generic competition","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total net revenue $42.3M (-36% YoY); U.S. net product revenue $30.6M (-51%) from generic competition and CVS delisting.","European net product revenue $4.3M (up from $0.8M); VAZKEPA sales grew 19% sequentially in Spain and UK.","Net loss $25.1M ($0.06/share) vs $19.3M loss ($0.05); non-GAAP adjusted net loss $20.4M ($0.05).","Cash and investments $305.7M, flat QoQ; reaffirms cash adequate for foreseeable future.","Company committed to maintaining public listing; exploring paths to resolve issue. Virtual Analyst Day Nov 14."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":166308000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201418,"accession_number":"0000950170-24-113227","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2024-10-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CFO Tom Reilly resigns effective Oct 23, 2024; interim CFO named","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Tom Reilly voluntarily resigns as EVP, CFO and Head of Global HR & Finance, effective October 23, 2024, to pursue another opportunity.","Resignation not due to any disagreement with the Company on financial statements, operations, policies or practices.","Vice President, Global Controller Peter Fishman assumes interim principal financial and accounting officer duties, reporting to CEO Aaron Berg.","Fishman has served as Global Controller since Oct 2022, with nearly 20 years of experience in accounting, financial reporting, tax, and audit.","Company is assessing next steps to identify a permanent CFO successor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217427,"accession_number":"0000950170-24-088234","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2024-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amarin Q2 revenue down 16% to $67.5M; PBM drops VASCEPA coverage; new CEO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total net revenue $67.5M (-16% YoY); net product revenue $47.5M (-27%) pressured by US generic competition.","GAAP net income $1.5M (EPS $0.00) vs net loss $17.6M in Q2 2023; non-GAAP adj. net income $5.9M.","Cash $306.7M; $50M share repurchase program approved but not commenced.","Large PBM removed VASCEPA from exclusive coverage for Commercial national formularies effective July 1, 2024.","CEO Aaron Berg appointed; China CVRR milestone $15M; new EU patent extending VAZKEPA exclusivity to 2039."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":124010000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217426,"accession_number":"0000950170-24-087391","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2024-07-29T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Amarin appoints Aaron Berg as CEO with $700K salary, performance options for 5M shares","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Berg's base salary $700K, eligible for cash incentive compensation; agrees to buy $100K of AMRN shares.","Performance-based option to purchase 5M shares; hurdles $1.25-$10.00 share price (60-day VWAP).","Severance: 18 months base + 0.975x base lump sum (outside change of control); 3.3x base within change of control period.","Option grant expected August 1, 2024; exercise price = closing price on grant date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237281,"accession_number":"0000950170-24-068298","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2024-06-04T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Amarin CEO resigns; large PBM to drop Vascepa coverage July 1, affecting 25% of US volume","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Pat Holt resigned; Aaron Berg appointed as President & CEO effective June 4, 2024.","Holt will provide consulting services through July 3, 2024 in exchange for his base salary.","A large national PBM will exclude Vascepa from commercial national formularies effective July 1, 2024.","Affected formularies represent ~25% of aggregate US Vascepa prescription volume; Medicare Part D unaffected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237280,"accession_number":"0000950170-24-065585","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2024-05-29T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Amarin receives Nasdaq deficiency notice over bid price below $1.00 for 30 days","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Amarin on May 24, 2024 that its ADS closing bid price has been below $1.00 for 30 consecutive business days.","Company has 180 calendar days, until November 20, 2024, to regain compliance by closing at $1.00 or more for 10 consecutive business days.","Failure by November 20 could lead to a second 180-day cure period if listing is transferred to Nasdaq Capital Market.","Amarin's ADSs continue to trade on The Nasdaq Global Market under symbol AMRN; no immediate delisting effect.","Company is evaluating options but cannot assure it will regain compliance with the Bid Price Requirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237279,"accession_number":"0000950170-24-050889","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amarin Q1 revenue $56.5M (-34% YoY); European in-market sales +65% QoQ; GAAP loss $0.02","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["U.S. net product revenue fell 41% YoY to $48.1M on generic price erosion; gross margin narrowed to 55% from adjusted 70% a year ago.","GAAP net loss $10.0M ($0.02/share) vs loss $16.5M ($0.04) Q1'23; non-GAAP adjusted net loss $4.7M ($0.01) vs income $7.6M ($0.02) YoY.","European in-market sales grew ~65% Q1'24 vs Q4'23, driven by Spain (+91% patients on therapy) and UK (+28%).","EPO issued new VAZKEPA patent extending IP protection in Europe until 2039; $50M share repurchase program approved, pending UK High Court OK in Q2.","Cash & investments $308.2M, stable over seven quarters; on track for $40M annual cost savings from July 2023 restructuring."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":56519000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237278,"accession_number":"0000950170-24-046290","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2024-04-22T23:59:59+00:00","items":["5.02","5.07","8.01","9.01"],"status":"ready","headline":"Amarin shareholders approve $50M share repurchase program and board declassification","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved two proposals enabling up to $50M share repurchase; final step is UK High Court approval, expected by end of Q2 2024.","Plan Amendment No. 3 to 2020 Stock Incentive Plan approved, increasing share reserve by 10 million ordinary shares/ADSs.","Resolutions passed: re-election of directors Holt, Sterling III, Bonfiglio; advisory say-on-pay; EY as auditor; declassified board requiring annual director elections.","Approximately 255 million shares (61% of eligible) were present and voting at the April 18, 2024 Annual General Meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}